Reglan Tardive Dyskinesia Attorney: Statute of Limitations for Reglan in New York

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

What is the statute of limitations for Reglan tardive dyskinesia lawsuits in New York

In New York, the statute of limitations for Reglan (metoclopramide) tardive dyskinesia lawsuits is generally three years from the date of injury or discovery. However, specific circumstances may affect this timeline. Consult a qualified attorney to evaluate your case and ensure compliance with applicable deadlines.

From Mass Production to Individual Risk: The Evolution of Health Communication

The legacy of mass production in health and science communication has long emphasized broad public awareness, delivering general information on wellness, disease prevention, and therapeutic options to diverse audiences. This foundation of accessible knowledge has empowered individuals to make informed decisions about their medical care, including understanding the benefits and risks associated with common prescription medications. Within this framework, the dissemination of general health information has historically focused on widely used treatments, such as metoclopramide—commonly known by the brand name Reglan—which has been prescribed for gastrointestinal conditions. As public health education evolved, it became increasingly important to address not only the intended effects of such medications but also the potential for adverse outcomes that may arise from prolonged or repeated use. This shift in focus naturally extends to a more specific concern: the occupational exposure risk faced by individuals who, due to their work environments, may have sustained or heightened contact with substances like Reglan. In mass production settings, workers in pharmaceutical manufacturing, healthcare facilities, or related industries could encounter this medication through handling, administration, or environmental contamination. Such occupational exposure raises distinct considerations regarding the timing of legal recourse, particularly in jurisdictions like New York, where statutes of limitations impose strict deadlines for filing claims related to conditions such as tardive dyskinesia. Understanding these temporal constraints is critical for those whose professional duties may have inadvertently contributed to their exposure history.

Understanding Reglan and Its Approved Uses

Reglan, the brand name for metoclopramide, is a medication approved for specific short-term uses in adults, including treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in patients who fail to respond to conventional therapy, and relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, a significant and serious adverse effect associated with metoclopramide is tardive dyskinesia (TD), a potentially irreversible movement disorder. The U.S. Food and Drug Administration (FDA) has issued a boxed warning, the strongest safety warning, regarding this risk. The warning states that metoclopramide, including Reglan, can cause TD, a potentially irreversible serious movement disorder, and that the risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and healthcare providers are advised to use Reglan for the shortest duration of treatment and periodically reassess the need for continued treatment. If signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Tardive Dyskinesia: Clinical Presentation and Mechanism

Tardive dyskinesia is characterized by involuntary, repetitive movements, often involving the face, tongue, and extremities. The clinical presentation can include grimacing, lip smacking, tongue protrusion, and rapid eye blinking. The condition can be disfiguring and, in some cases, may persist even after the medication is stopped. The mechanistic pathway linking metoclopramide to TD involves its action as a dopamine receptor antagonist. Metoclopramide blocks dopamine D2 receptors in the brain, which can lead to supersensitivity of these receptors over time, contributing to the development of abnormal involuntary movements. The FDA label notes that metoclopramide may also suppress or partially suppress the signs of TD, potentially delaying diagnosis because it may mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Statute of Limitations for Reglan Claims in New York

For patients in New York who have developed TD after using Reglan, understanding the statute of limitations is critical for any legal action. The statute of limitations sets a time limit on when a lawsuit can be filed. In New York, personal injury claims, including those related to medication side effects, generally must be filed within three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. However, the specific timeline can vary based on the circumstances of the case, such as when the patient first noticed symptoms or when a diagnosis of TD was made. Given the potentially delayed onset of TD, which can occur months or even years after starting metoclopramide, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Reglan caused the harm. The adequacy of warnings regarding Reglan and TD is a key consideration in legal claims. The FDA boxed warning clearly states the risk, but questions may arise about whether healthcare providers and patients were adequately informed, especially if the medication was used for longer than the recommended 12-week maximum for gastroesophageal reflux or if it was prescribed off-label for extended periods. The label explicitly states that Reglan has not been shown to be safe and effective for gastroesophageal reflux for longer than 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, the label advises avoiding a total duration of treatment longer than 12 weeks, and if longer-term use is unavoidable, to routinely monitor for signs and symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Additionally, Reglan tablets are not recommended for use in pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Legal Considerations for Affected Patients

Attorney-related considerations for affected patients include the need to gather medical records documenting the prescription and use of Reglan, the onset and diagnosis of TD, and any communications with healthcare providers about the risks. Expert testimony may be required to establish the link between Reglan use and the development of TD, as well as to assess whether the warnings were sufficient. The timeline between exposure to Reglan and documented harm is crucial; patients who used Reglan for extended periods, such as months or years, may have a stronger case, as the risk increases with longer treatment duration and higher cumulative doses. In summary, Reglan carries a known risk of causing tardive dyskinesia, a potentially irreversible movement disorder, with the risk increasing with longer use. Patients in New York who have developed TD after using Reglan should be aware of the statute of limitations for filing a claim, which generally requires action within three years of discovering the injury. Legal evaluation should consider the adequacy of warnings, the duration of Reglan use, and the timeline of symptom onset. Consulting with an attorney experienced in pharmaceutical litigation is advisable to navigate these complex issues.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in New York?

In New York, personal injury claims for medication side effects generally must be filed within three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. The discovery rule may apply for tardive dyskinesia due to its potentially delayed onset.

Can Reglan cause tardive dyskinesia even after short-term use?

Yes, although the risk increases with longer duration of treatment and higher cumulative dosage, tardive dyskinesia can occur even after short-term use. The FDA boxed warning emphasizes that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.